The clinical and economic burden of poor adherence and persistence with osteoporosis medications in ireland.

Hdl Handle:
http://hdl.handle.net/10147/240208
Title:
The clinical and economic burden of poor adherence and persistence with osteoporosis medications in ireland.
Authors:
Hiligsmann, Mickaël; McGowan, Bernie; Bennett, Kathleen; Barry, Michael; Reginster, Jean-Yves
Affiliation:
Departments of Internal Medicine and of Clinical Epidemiology and Medical Technology Assessment, CAPHRI Research Institute, Maastricht University, Maastricht, The Netherlands; Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium; HEC School of Management, University of Liège, Liège, Belgium.
Citation:
The clinical and economic burden of poor adherence and persistence with osteoporosis medications in ireland. 2012, 15 (5):604-12 Value Health
Journal:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Issue Date:
Jul-2012
URI:
http://hdl.handle.net/10147/240208
DOI:
10.1016/j.jval.2012.02.001
PubMed ID:
22867768
Abstract:
Medication nonadherence is common for osteoporosis, but its consequences have not been well described. This study aimed to quantify the clinical and economic impacts of poor adherence and to evaluate the potential cost-effectiveness of improving patient adherence by using hypothetical behavioral interventions.; A previously validated Markov microsimulation model was adapted to the Irish setting to estimate lifetime costs and outcomes (fractures and quality-adjusted life-year [QALY]) for three adherence scenarios: no treatment, real-world adherence, and full adherence over 3 years. The real-world scenario employed adherence and persistence data from the Irish Health Services Executive-Primary Care Reimbursement Services pharmacy claims database. We also investigated the cost-effectiveness of hypothetical behavioral interventions to improve medication adherence (according to their cost and effect on adherence).; The number of fractures prevented and the QALY gain obtained at real-world adherence levels represented only 57% and 56% of those expected with full adherence, respectively. The costs per QALY gained of real-world adherence and of full adherence compared with no treatment were estimated at €11,834 and €6,341, respectively. An intervention to improve adherence by 25% would result in an incremental cost-effectiveness ratio of €11,511 per QALY and €54,182 per QALY, compared with real-world adherence, if the intervention cost an additional €50 and €100 per year, respectively.; Poor adherence with osteoporosis medications results in around a 50% reduction in the potential benefits observed in clinical trials and a doubling of the cost per QALY gained from these medications. Depending on their costs and outcomes, programs to improve adherence have the potential to be an efficient use of resources.
Item Type:
Article
Language:
en
ISSN:
1524-4733

Full metadata record

DC FieldValue Language
dc.contributor.authorHiligsmann, Mickaëlen_GB
dc.contributor.authorMcGowan, Bernieen_GB
dc.contributor.authorBennett, Kathleenen_GB
dc.contributor.authorBarry, Michaelen_GB
dc.contributor.authorReginster, Jean-Yvesen_GB
dc.date.accessioned2012-08-28T13:07:58Z-
dc.date.available2012-08-28T13:07:58Z-
dc.date.issued2012-07-
dc.identifier.citationThe clinical and economic burden of poor adherence and persistence with osteoporosis medications in ireland. 2012, 15 (5):604-12 Value Healthen_GB
dc.identifier.issn1524-4733-
dc.identifier.pmid22867768-
dc.identifier.doi10.1016/j.jval.2012.02.001-
dc.identifier.urihttp://hdl.handle.net/10147/240208-
dc.description.abstractMedication nonadherence is common for osteoporosis, but its consequences have not been well described. This study aimed to quantify the clinical and economic impacts of poor adherence and to evaluate the potential cost-effectiveness of improving patient adherence by using hypothetical behavioral interventions.-
dc.description.abstractA previously validated Markov microsimulation model was adapted to the Irish setting to estimate lifetime costs and outcomes (fractures and quality-adjusted life-year [QALY]) for three adherence scenarios: no treatment, real-world adherence, and full adherence over 3 years. The real-world scenario employed adherence and persistence data from the Irish Health Services Executive-Primary Care Reimbursement Services pharmacy claims database. We also investigated the cost-effectiveness of hypothetical behavioral interventions to improve medication adherence (according to their cost and effect on adherence).-
dc.description.abstractThe number of fractures prevented and the QALY gain obtained at real-world adherence levels represented only 57% and 56% of those expected with full adherence, respectively. The costs per QALY gained of real-world adherence and of full adherence compared with no treatment were estimated at €11,834 and €6,341, respectively. An intervention to improve adherence by 25% would result in an incremental cost-effectiveness ratio of €11,511 per QALY and €54,182 per QALY, compared with real-world adherence, if the intervention cost an additional €50 and €100 per year, respectively.-
dc.description.abstractPoor adherence with osteoporosis medications results in around a 50% reduction in the potential benefits observed in clinical trials and a doubling of the cost per QALY gained from these medications. Depending on their costs and outcomes, programs to improve adherence have the potential to be an efficient use of resources.-
dc.language.isoenen
dc.rightsArchived with thanks to Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Researchen_GB
dc.titleThe clinical and economic burden of poor adherence and persistence with osteoporosis medications in ireland.en_GB
dc.typeArticleen
dc.contributor.departmentDepartments of Internal Medicine and of Clinical Epidemiology and Medical Technology Assessment, CAPHRI Research Institute, Maastricht University, Maastricht, The Netherlands; Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium; HEC School of Management, University of Liège, Liège, Belgium.en_GB
dc.identifier.journalValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Researchen_GB

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.